VTI ETF Daily Briefing: Key Information for Investors – November 7, 2025
VTI ETF Performance: The Vanguard Total Stock Market ETF (VTI) is down 2.72% over the past week but has increased by 14.71% year-to-date, with a recent decline of 1.17% on Thursday amid broader market pressures on tech stocks.
Investor Activity and Technical Indicators: VTI saw $382 million in net inflows over the last five days, maintaining a bullish trend as it trades above its 50-day moving average, with a current price of $329.37.
Analyst Ratings and Price Target: VTI holds a Moderate Buy rating from analysts, with an average price target of $387.73, suggesting a potential upside of 17.72%.
Top Holdings and Upside Potential: The ETF's largest holdings include Nvidia, Microsoft, and Apple, while its top five holdings with the highest upside potential are various biotech companies, indicating a mixed outlook on individual stock performance.
Get Free Real-Time Notifications for Any Stock
Analyst Views on SGMO
About SGMO
About the author

Sangamo Initiates BLA Submission for ST-920, Expected in Q2 2026
- Clinical Trial Success: Sangamo's STAAR study demonstrated a positive mean annualized eGFR slope at 52 weeks across all dosed patients, with the FDA agreeing to use this as an endpoint for accelerated approval, indicating ST-920's potential as an effective treatment for Fabry disease patients.
- Favorable Safety Profile: Isaralgagene civaparvovec exhibited a favorable safety and tolerability profile in clinical trials, suggesting its potential as a one-time gene therapy that can provide durable clinical benefits, surpassing current treatment standards for Fabry disease.
- Accelerated Approval Pathway: Sangamo expects to complete its Biological License Application (BLA) submission to the FDA in the second quarter of 2026 using a rolling submission approach, allowing for ongoing review of completed modules, thereby expediting the approval process to meet urgent patient needs.
- Regulatory Support: Isaralgagene civaparvovec has received Orphan Drug, Fast Track, and RMAT designations from the FDA, along with Orphan Medicinal Product designation from the European Medicines Agency, highlighting its potential value and regulatory recognition in global markets, further enhancing Sangamo's competitive position.

Sangamo Initiates BLA Submission for ST-920, Expected Completion in Q2 2026
- Clinical Trial Results: Sangamo's STAAR study demonstrated a positive mean annualized eGFR slope at 52 weeks across all dosed patients, with the FDA agreeing to use this as an endpoint for accelerated approval, indicating ST-920's potential in treating Fabry disease.
- Safety Profile: Isaralgagene civaparvovec has shown a favorable safety and tolerability profile, expected to provide a safe and durable treatment option for Fabry patients, significantly improving multi-organ clinical benefits.
- Submission Timeline: Sangamo plans to complete its Biological License Application (BLA) submission in Q2 2026 using a rolling submission approach, allowing the FDA to review completed modules continuously, thus expediting the approval process.
- Regulatory Support: The therapy has received Orphan Drug, Fast Track, and RMAT designations from the FDA, reflecting regulatory recognition of its potential market value and enhancing Sangamo's competitive position in the gene therapy sector.









